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Introduction: Bone marrow derived cellular therapies are an emerging approach to promoting therapeutic
angiogenesis in ischemic cardiovascular disease. However, the percentage of regenerative cells in bone marrow
mononuclear cells (BMMNCs) is small, and large amounts of BMMNCs are required. Ixmyelocel-T, an expanded
autologous multicellular therapy, is manufactured from a small sample of bone marrow aspirate. Ixmyelocel-T
contains expanded populations of mesenchymal stromal cells (MSCs) and M2-like macrophages, as well as many of
the CD45+ cells found in the bone marrow. It is hypothesized that this expanded multi-cellular therapy would
induce angiogenesis and endothelial repair.
Methods: A rat model of hind limb ischemia was used to determine the effects of ixmyelocel-T on blood flow
recovery. To further determine the effects on endothelial cells, ixmyelocel-T was co-cultured with human umbilical
vein endothelial cells (HUVEC) in non-contacting Transwell® inserts.
Results: Co-culture of HUVECs with ixmyelocel-T resulted secretion of a variety of pro-angiogenic factors. HUVECs
stimulated by ixmyelocel-T exhibited enhanced migration, proliferation, and branch formation. Ixmyelocel-T co-culture
also resulted in increased endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production. In
tumor necrosis factor alpha (TNFα)-stimulated HUVECs, ixmyelocel-T co-culture decreased apoptosis and reactive
oxygen species generation, increased super oxide dismutase activity, and decreased nuclear factor kappa B (NFκB)
activation. Treatment with ixmyelocel-T in a rat model of hind limb ischemia resulted in significantly increased
blood flow perfusion and capillary density, gene expression and plasma levels of the anti-inflammatory cytokine
interleukin (IL)-10, plasma nitrates, plasma platelet-derived growth factor (PDGF)-BB, vascular endothelial growth
factor (VEGF) expression, and significantly decreased plasma thiobarbituric acid reactive substances (TBARS).
Conclusions: This work demonstrates that ixmyelocel-T interacts with endothelial cells in a paracrine manner,
resulting in angiogenesis and endothelial protection. This data suggests that ixmyelocel-T could be useful for promoting
of angiogenesis and tissue repair in ischemic cardiovascular diseases. In conclusion, ixmyelocel-T therapy may provide a
new aspect of therapeutic angiogenesis in this patient population where expanded populations of regenerative cells
might be required.* Correspondence: rtubo@vcel.com
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Ischemic cardiovascular (CV) disease, a leading cause of
mortality in the western world, is a systemic inflamma-
tory disease involving dysfunction of the endothelium.
The disease can lead to development of peripheral arter-
ial disease, an atherosclerotic disease that results in inad-
equate blood flow to the extremities and eventually
critical limb ischemia (CLI) [1,2]. The prevalence of per-
ipheral arterial disease is rapidly increasing, and cur-
rently affects 8 to 12 million people in the United States
[3]. Patients with CLI often have poor prognosis, leading
to amputation of the lower extremities [1]. Several alter-
native approaches are currently under investigation for
the treatment of CLI since only partial or short-term
benefits are exhibited in current interventional therapies
[1,2]. One alternative approach to treating CLI is the
intramuscular administration of bone marrow-derived
cellular-based therapies. These therapies are thought to
contribute to tissue regeneration and repair in areas of
tissue ischemia predominantly through secretion of
paracrine factors [4,5]. Unfortunately, the percentage of
regenerative cells in bone marrow mononuclear cells
(BMMNCs) is small, and a large amount of BMMNCs is
required in order to induce restorative angiogenesis [6].
Efforts are therefore needed to identify novel cellular
therapies consisting of expanded populations of regen-
erative cells that have the ability to promote therapeutic
angiogenesis in advanced disease states.
Ixmyelocel-T is an expanded, autologous multicellular
therapy containing a mixture of cell types cultured from
BMMNC [2,7]. Ixmyelocel-T is manufactured from a
small sample of bone marrow aspirate expanded for
12 ± 1 days in a fully closed automated bioreactor sys-
tem, and is composed of a mixture of cells – including
myeloid cells (macrophages, granulocytes, monocytes,
and mixed myeloid progenitors), lymphoid cells (T cells,
B cells, and a mixture of lymphoid precursors) and
mesenchymal stromal cells (MSCs) [7]. The process used
to generate this cell therapy expands both the CD90+
MSCs and CD14+ macrophages, while retaining many of
the CD45+ cells found in the bone marrow since the
process does not utilize any purification or enrichment
steps, other than phenotypic expansion [7]. The CD14+
macrophages are M2-like, with expression of two M2
surface receptors CD206 and CD163 [7,8]. Recent clinical
trials evaluating ixmyelocel-T therapy in the treatment of
the ischemic CV diseases dilated cardiomyopathy and CLI
have shown clinical promise [2,9]. A phase 2a study in
dilated cardiomyopathy (the IMPACT-DCM trial) demon-
strated that ischemic patients receiving ixmyelocel-T
experienced a lower percentage of major adverse cardiac
events compared with control [7]. A phase 2b study in
CLI (the RESTORE-CLI trial) demonstrated that treat-
ment with ixmyelocel-T was safe and improved the timeto first occurrence of treatment failure [2,7]. It is hypothe-
sized that this expanded multicellular therapy has the
potential to be a promising treatment in ischemic CV
diseases where angiogenesis and tissue repair are essential.
In the present study, a rat model of hind-limb ischemia
and human umbilical vein endothelial cells (HUVECs)
were utilized to determine whether ixmyelocel-T pro-
motes angiogenesis and regeneration. Specifically, the abil-
ity of ixmyelocel-T to restore blood flow and promote
angiogenesis in vivo and in vitro was examined.
Methods
Cell culture
HUVECs (Lonza Inc., Walkersville, MD, USA) were cul-
tured in EGM-2 (Lonza, Inc.). HUVECs between pas-
sages 3 and 8 were used in the following experiments.
For the generation of ixmyelocel-T, a small volume
(~50 ml) of commercially available whole bone marrow
(Lonza Inc.) was obtained from healthy donors, under
informed consent, through needle aspiration of the pos-
terior iliac crest, and stored in heparinized tubes during
shipment at ambient temperature to a central processing
facility. The mononuclear cell fraction was obtained via
an automated, closed-system, Ficoll-based density gradient
centrifugation separation process. The isolated mono-
nuclear cells were then transferred to a sterile, single-use
cell bioreactor cassette [7,10]. This proprietary system
controlled temperature, culture medium exchange, and
gas exchange during the culture period. After approxi-
mately 12 days, the cells were washed and harvested from
the cassette by a multistep, automated process, and ready
for experimental study. All experiments were performed
with multiple donors, with each donor being considered
one number.
Rat hind-limb ischemia model
All procedures were conducted in accordance with the
current guidelines for animal welfare (Guide for the Care
and Use of Laboratory Animals, 1966). The procedures
used in this study were reviewed and approved by the
Michigan State University In Vivo Pharmacology Facility’s
Institutional Animal Care and Use Committee. Eight-
weeks-old male RNU Nude rats (purchased from Charles
River, Horsham, Pennsylvania, USA) underwent unilateral
hind-limb ischemia. In brief, under anesthesia an incision
was made along the inguinal groove and the femoral artery
was isolated from its origin at the external iliac artery to the
distal segment where it bifurcates in the popliteal and
saphenous arteries. The artery was ligated proximally and
distally with a silk suture and a portion of the artery
(<4 mm) was excised. The incision was closed and animals
were allowed to recover from anesthesia. Laser Doppler
tissue imaging showed that obstruction of the left femoral
artery decreased blood perfusion by approximately 90% at
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ment groups: vehicle, or ixmyelocel-T treated (n = 4). After
2 weeks the animals received four intramuscular injections
totaling 2 × 106 cells or vehicle in the ischemic limb.
Laser Doppler assessment of blood flow
Hind-limb perfusion of all animals was assessed prior
to surgery using a PeriScan PIM 3 (Perimed AB,
Stockholm, Sweden) scanning laser Doppler perfusion
imaging system. Ischemia was confirmed in all animals
immediately following femoral artery ligation. Blood flow
was then measured 14, 42, and 56 days after surgery.
After blood flow had been imaged three times, the aver-
age blood flow was calculated. The perfusion ratio was
defined as blood flow in the ligated limb normalized to
baseline. For these studies, normalization to baseline
was used since treatment with ixmyelocel-T resulted in
increased blood flow in the nonischemic limb, thus not
allowing normalization to the nonischemic limb.
Capillary density
To detect capillary endothelial cells, the frozen sections
of the quadriceps muscles (n = 4) were stained with
CD31 (Santa Cruz, California, CA). Briefly, ischemic limb
muscles were harvested at day 56 after treatment and
embedded in optimal cutting temperature compound
(Tissue-Tek; Sakura, Torrance, California, USA) com-
pound. Frozen sections were stained with CD31 to examine
capillary density. Three fields were randomly selected to
calculate the number of capillaries in each field. Capillary
density was expressed as number of capillaries per myocyte.
Assessment of marker in plasma
Blood was collected at time of sacrifice. Plasma nitrates
and thiobarbituric acid reactive substances (TBARS)
were measured in the collected blood plasma using the
Cayman Chemical Nitrate Fluorometric Assay (Cayman
Chemical, Ann Arbor, MI, USA) and the Cayman
Chemical TBARS Assay. Enzyme-linked immunosorbent
assay (ELISA) kits were used to determine the concen-
trations of platelet-derived growth factor (PDGF)-BB
and interleukin (IL)-10 (n ≥3; R&D Systems, Minneapolis,
MN, USA).
Survival/engraftment of ixmyelocel-T in ischemic hind
limb
For detection of transplanted ixmyelocel-T, the cells were
labeled with PKH26 (Sigma, St Louis, Mo, USA), a fluor-
escent cell linker dye, following the manufacturer’s proto-
col. Nude rats received intramuscular injections of 2 × 106
PKH26-labeled ixmyelocel-T in the ischemic limb. After
8 days the ischemic muscles were excised, embedded in
optimal cutting temperature compound, and visualized
for PKH26-labeled cells. Frozen tissue sections were alsostained with human specific anti-nuclei monoclonal anti-
body (Chemicon Merck Millipore, Darmstadt, Germany).
Primary antibody was incubated for 30 minutes at room
temperature prior to incubation with fluorochrome-
tagged secondary antibody for 30 minutes. Counterstain-
ing was performed with 4′-6-diamidino-2-phenylindole to
visualize nuclei. Fluorescent images (n = 4) were visualized
using a Nikon Eclipse 80i (Nikon, Melville, NY, USA)
equipped with an EXi Aqua Bio-Imaging Microscopy
Camera (Q Imaging, Surrey, BC, Canada).
Flow cytometry
For cell surface staining, erythrocytes were lysed with
lysing solution for 10 minutes (Becton Dickinson, San
Jose, CA, USA). Fc receptors were blocked with Fc re-
ceptor blocking agent (Miltenyi Biotech, Auburn, CA,
USA) for 15 minutes at 4°C. Cells were then incubated
with surface receptor antibodies for 15 minutes at 4°C,
and then washed with phosphate-buffered saline. Cell
surface staining was analyzed using the Gallios flow cyt-
ometer (Beckman Coulter, Brea, CA, USA). Kaluza soft-
ware (Beckman Coulter) was used to analyze the acquired
data.
Co-culture
Noncontacting co-culture transwell cell culture systems
were developed in order to study the cross-biological ac-
tivity of HUVECs and ixmyelocel-T. This co-culture sys-
tem allowed for bidirectional diffusion of soluble factors.
The co-cultured cells were prepared as follows. HUVECs
were plated on the bottom of cell culture plates (Costar;
Sigma Aldrich, St. Louis, MO, USA) and allowed to ad-
here in EGM-2 (Lonza Inc.). The cells were then washed
with serum-free medium and incubated overnight in
growth factor-free endothelial cell base media-2 (EBM-2;
Lonza Inc.) with 0.05% fetal bovine serum. This served
as a control medium throughout the co-culture experi-
ments. Ixmyelocel-T was plated separately in transwell
inserts (pore size 0.4 μm; Corning Inc., Corning, NY,
USA) in control medium at a ratio of 1:2 (HUVECs:
ixmyelocel-T). The transwell inserts containing ixmyelocel-T
were then placed into the plates containing HUVECs to ini-
tiate the experiments. Co-culture plates were then incubated
at 37°C in a humidified air/carbon dioxide (95:5, v/v) atmos-
phere for 2 or 24 hours. After the incubation period, the
co-culture inserts were removed and discarded. The
HUVECs were then used in the following experiments.
Enzyme-linked immunosorbent assay
ELISA kits were used to determine the concentrations of
intracellular endothelial nitric oxide synthase (eNOS; R&D
Systems). Supernatants from six-well plates containing the
HUVECs were collected after the cell culture insert was
removed. Intracellular analysis of eNOS was carried out
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brief, HUVECs were washed with phosphate-buffered sa-
line and lysed with R&D cell lysis buffer (R&D Systems).
The cell lysates were centrifuged and the supernatants were
then assayed following the manufacturer’s instructions.
Nitric oxide synthase assay and nitrates
Nitric oxide synthase (NOS) was measured using the NOS
detection kit (Cell Technology Inc, Mountain View, CA,
USA). HUVECs were loaded with diaminofluorescein-2
diacetate, a nonfluorescent cell-permeable reagent that
can measure free nitric oxide (NO) and NOS activity in
living cells, for 1 hour at 37°C. HUVECs were then co-
cultured with ixmyelocel-T or medium (control). Intra-
cellular NOS activity was then measured following the
manufacturer’s instructions (n ≥9). Nitrates were mea-
sured in cell culture supernatants using the Cayman
Chemical Nitrate Fluorometric Assay (n ≥8).
Intracellular reactive oxygen species assay
Intracellular reactive oxygen species (ROS) generation
was measured using a commercially available intra-
cellular ROS assay (Cell Biolabs Inc., San Diego, CA,
USA). Briefly, HUVECs were loaded with the fluorescent
probe DCFH-DA for 1 hour at 37°C. HUVECs were then
stimulated with 10 ng/ml tumor necrosis factor alpha
(TNFα; R&D Systems) for 4 hours. The concentration of
TNFα used to induce inflammation and oxidative stress
was based upon our preliminary dose-finding study and
the previous research of other laboratories [11,12], which
demonstrate that 10 ng/ml TNFα significantly increase
endothelial oxidative stress and inflammation. The cells
were then washed with serum-free medium, and co-
cultured with ixmyelocel-T or medium (control) for
2 hours. Intracellular levels of ROS were then measured
following the manufacturer’s instructions (n ≥6).
Measurement of intracellular superoxide dismutase
activity
Intracellular superoxide dismutase (SOD) was measured
using a commercially available SOD Assay (n ≥4; Cell
Biolabs Inc.). Briefly, HUVECs were stimulated with
10 ng/ml TNFα (R&D Systems) for 4 hours. The cells
were then washed with serum-free medium, and co-
cultured with ixmyelocel-T or medium (control) for
2 hours. Intracellular levels of SOD were then measured
following the manufacturer’s instructions.
Immunofluorescence
Immunofluorescence of eNOS was evaluated in HUVECs
co-cultured with ixmyelocel-T or medium (control)
(n ≥3). Briefly, HUVECs were grown on coverslips in
six-well culture dishes. Ixmyelocel-T or medium (control)
were then placed in co-culture inserts and co-culturedwith the HUVECs for 2 hours. The co-cultures were then
removed, and the HUVECs were fixed with 10% formalin
for 10 minutes. Each cover slip was stained with eNOS
antibody (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) for 2 hours at room temperature prior to
incubation with fluorochrome-tagged secondary antibody
for 30 minutes. Counterstaining was performed with 4′-
6-diamidino-2-phenylindole to visualize nuclei. Fluores-
cent images were visualized using a Nikon Eclipse 80i
equipped with an EXi Aqua Bio-Imaging Microscopy
Camera (Q Imaging).Assessment of apoptosis
Apoptosis was measured in HUVECs that were plated in
96-well plates, starved overnight in control medium,
followed by induction of apoptosis with 100 ng/ml TNFα
(R&D Systems) for 6 hours (n = 6). The concentration of
TNFα used to induce apoptosis was based upon our
preliminary dose-finding study and previous findings [13].
Viability and induction of apoptosis were examined by
measuring caspase-3 and caspase-7 activity using the
Apo-Tox assay (Promega, Wallisellen, Switzerland). Both
fluorescence and luminescence units were measured using
a SpectraMax plate reader (Molecular Devices, Sunnyvale,
CA, USA) and values were expressed relative to those
obtained from the HUVEC control group.Real-time PCR
For real-time PCR, total RNA was extracted with an
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and 1 μg
RNA was reverse transcribed using a high-capacity
cDNA reverse transcription kit (Applied Biosciences,
Carlsbad, CA, USA). Relative levels of target gene ex-
pression were measured on the 7500 Real-Time PCR
system (Applied Biosystems). The FAM-based Taqman
Gene Expression Assay Mix (Applied Biosystems) spe-
cific for each gene of interest and Taqman Universal
Master Mix (Applied Biosystems) were used. Relative
quantification PCR analysis was performed using the
ABI 7500 Software (Applied Biosystems). The relative
amount of cDNA was calculated by normalization to
glyceraldehyde 3-phosphate dehydrogenase.Proliferation assay
HUVECs were seeded at a density of 5 × 103 cells per
well in 96 well transwell insert plates (Corning Inc.) and
co-cultured with varying concentrations of ixmyelocel-T
plated in inserts for 72 hours (n ≥4). Proliferation was
measured by incubation with bromodeoxyuridine at a
final concentration of 10 mM. Bromodeoxyuridine in-
corporation was measured by a commercially available
ELISA (Cell Signaling Technology, Danvers, MA, USA).
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HUVECs were seeded in 24-well plates and allowed to form
confluent monolayers. Cells were then cultured in serum
starvation media (EBM-2 + 0.05% fetal bovine serum) over-
night. Monolayers were scratched using a sterile 200 μl pip-
ette tip. Cells were washed with phosphate-buffered saline,
and fresh serum starvation media (EBM-2 + 0.05% fetal bo-
vine serum) was replaced. Images were taken for the start-
ing point of each scratch using a Nikon Eclipse TE2000-S
Microscope (Nikon, Tokyo, Japan) equipped with a Spot
Xplorer Leica digital camera (SPOT, Sterling Heights, MI,
USA). Ixmyelocel-T was plated in transwell cell culture
plates (pore size 0.4 μm; Corning Inc.) in serum-free
HUVEC media. The plate was then placed in an incubator
for 16 hours, after which scratches were imaged. Changes
in wound width were calculated using ImageJ software
(National Institutes of Health, Besthesda, Maryland, USA).
Assays were performed in triplicate (n ≥4).
Matrigel assays
HUVECs were seeded at a density of 5 × 104 cells per
well in 24-well Matrigel-coated (BD Bioscience) plates.
Ixmyelocel-T was plated onto Transwell inserts (24-well
clusters, 0.4 μm pore size; Corning Inc.) at varying dens-
ities. Tube branch formation and length was measured
after 8 hours of co-culture in three random microscopic
fields taken at 10× magnification (n ≥4). Tube branch
formation and length were quantified with the ImageJ
analysis software.
Cytokine arrays
To identify angiogenic factors secreted by HUVECs and by
HUVECs co-cultured with ixmyelocel-T, the protein levels
of specific factors in cell-conditioned medium were mea-
sured (n ≥3). Cytokine arrays were performed according
to manufacturer’s protocols (RayBiotech Inc., Norcross,
Georgia, USA) in conditioned medium. Briefly, HUVECs
were stimulated with 10 ng/ml TNFα (R&D Systems) for
4 hours. The cells were then washed with serum-free
medium, and co-cultured with ixmyelocel-T or medium
(control) for 24 hours, after which the supernatants were
collected for analysis.
Statistical analysis
A paired t test was performed to compare results. P <0.05
was considered statistically significant. Data are reported
as mean ± standard error of the mean.
Results
Ixmyelocel-T contains expanded populations of
regenerative cells
Ixmyelocel-T is composed of a mixture of cells, includ-
ing myeloid cells, lymphoid cells, and MSCs/stromal
cells [7]. As reported previously, the two main cell typesexpanded from BMMNCs in Aastrom’s manufacturing
process are CD90+ MSCs and CD14+ macrophages [7].
Figure 1 displays microscopy images of ixmyelocel-T
taken throughout the culture process to highlight the
expansion that occurs during culture (Figure 1A), and
flow cytometry analysis highlights the two regenerative
populations that are expanded in this culture process
(Figure 1B).
Ixmyelocel-T secretes multiple angiogenic cytokines and
growth factors when co-cultured with endothelial cells
Since it has been reported previously that the benefits of
cell therapies, such as angiogenesis, are mainly due to
paracrine effects [4], a cytokine array was utilized to
determine what proangiogenic factors ixmyelocel-T se-
cretes during co-culture with endothelial cells. Secretion
of several proangiogenic and proliferative factors were
quantified using a cytokine array (Table 1). Specifically,
the cytokines IL-3, IL-6, and IL-8, the chemokines CXCL5,
CCL1, and CCL7, macrophage migration inhibitory factor,
and growth factors PDGF-BB, epidermal growth factor,
hepatocyte growth factor, placental growth factor, angio-
genin, and osteoprotegerin were elevated in the superna-
tants from the HUVECs co-cultured with ixmyelocel-T
(Table 1). These results suggest that ixmyelocel-T has the
potential to promote angiogenesis and vascular repair
through the secretion of a variety of proangiogenic factors.
Ixmyelocel-T promotes the angiogenic capacity of
endothelial cells in vitro
To determine whether ixmyelocel-T promoted the angio-
genic activity of endothelial cells, ixmyelocel-T was co-
cultured with HUVECs using noncontacting co-culture
inserts. To determine whether ixmyelocel-T promotes
endothelial cell migration, an in vitro scratch assay was
employed. HUVEC co-cultures with ixmyelocel-T exhibited
significantly increased cell migration (59 ± 3.7 vs. 38 ± 3.4%
migration, P <0.001 compared with HUVECs; Figure 2A).
The effect of ixmyelocel-T on the induction of capillary-
like structures (angiogenesis and neovascularization)
in vitro was examined using a well-established model –
the Matrigel in vitro angiogenesis assay. HUEVCS were
grown on Matrigel-coated plates in serum-free conditions.
Co-culture with ixmyelocel-T increased branch formation
(16 ± 0.5 vs. 11 ± 1.3 branch number, P <0.01 compared
with HUVECs; Figure 2B-C) and tube length (131 ± 4 vs.
100 ± 6%, P <0.001 compared with HUVECs; Figure 2D).
To determine whether ixmyelocel-T promotes endothelial
proliferation, ixmyelocel-T was co-cultured with HUVECs
and analyzed using a bromodeoxyuridine proliferation
assay. Co-culture of HUVECs with ixmyelocel-T resulted
in significantly increased endothelial proliferation
(112 ± 6 vs. 100 ± 2% of HUVECs, P <0.05 compared






















Figure 1 Ixmyelocel-T is a multicellular therapy containing expanded populations of CD90+ mesenchymal stem cells and CD14+ M2-like
macrophages. (A) Phase imaging depicts the expansion of cells during the culture process. (B) Kinetics of ixmyelocel-T culture. Magnification:
20×. FACS, fluorescence-activated cell sorting.
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increased eNOS expression and nitric oxide production
NO regulates blood flow recovery after ischemia and ex-
erts multiple signaling events resulting in endothelial
proliferation, migration, and survival [14]. HUVECs were
co-cultured with ixmyelocel-T and eNOS expression was
examined. Immunofluorescence of eNOS was significantly
greater in HUVECs co-cultured with ixmyelocel-T com-
pared with HUVECs alone (1.3 ± 0.11 vs. 1.0 ± 0.01
relative intensity, P <0.01; Figure 3A). There were also
statistically significant higher intracellular levels of
eNOS in HUVECs co-cultured with ixmyelocel-T com-
pared with HUVECs alone (1,730 ± 141 vs. 1,371 ±
135 pg/ml, P <0.05; Figure 3B) measured by ELISA. NO
production was assessed with the intracellular probe
diaminofluorescein-2 diacetate. HUVECs co-cultured
with ixmyelocel-T displayed a statistically significant in-
crease in NO production compared with HUVECs alone
(1.97 ± 0.17 vs. 1 ± 0.09 relative fluorescence, P <0.001;
Figure 3C). Nitrates were also measured in the superna-
tants of the co-cultured cells as a marker of NO produc-
tion. HUVECs co-cultured with ixmyelocel-T had
statistically significant increased levels of nitrates intheir supernatants compared with HUVECs (39 ± 5 vs.
30 ± 3 μM, P <0.05; Figure 3D). These data suggest that
ixmyelocel-T promotes NO production in endothelial
cells.
Ixmyelocel-T attenuates apoptosis and inflammation
when co-cultured with TNFα-stimulated endothelial cells
Ixmyelocel-T was characterized previously with anti-
inflammatory properties [7,15], and thus the effects of
ixmyelocel-T on proinflammatory stimulated endothelial
cells was examined. Apoptosis of endothelial cells dis-
rupts the integrity of the endothelial monolayer, contrib-
uting to the initiation of proinflammatory events [16].
To induce vascular injury, HUVECs were pretreated
with TNFα. This TNFα stimulation increased endothelial
cell apoptosis (0.64 ± 0.07 vs. 1 ± 0.05 relative to HUVECs,
P <0.001 compared with HUVECs + TNFα; Figure 4A)
and decreased cell viability (1.74 ± 0.27 vs. 1 ± 0.03 relative
to HUVECs, P <0.05 compared with HUVECs + TNFα;
Figure 4B). Co-culture with ixmyelocel-T resulted in a
statistically significant increase in HUVEC viability
(1.14 ± 0.04 vs. 1 ± 0.03 relative to HUVECs, P <0.01
compared with HUVECs + TNFα; Figure 4B) and decrease
Table 1 Cytokine secretion
HUVECs IXT HUVECs + IXT
Interleukin-3 181 ± 15 240 ± 20* 229 ± 24
Interleukin-6 9,610 ± 808 9,201 ± 7,368 59,567 ± 3,801***,‡
Interleukin-8 16,525 ± 1,697 36,998 ± 5,957** 35,128 ± 9,227
CXCL5 205 ± 34 7,893 ± 4,630 9,385 ± 1,710**
CCL1 83 ± 3 28 ± 8*** 204 ± 39*,†
CCL7 67 ± 11 10,563 ± 1,748** 13,901 ± 3821**
MIF 3,765 ± 761 5,234 ± 1,556 5,364 ± 1,114
VEGF 15 ± 4 428 ± 275 95 ± 57
PDGF-BB 225 ± 29 34 ± 2*** 1,065 ± 345*,†
EGF 171 ± 51 17 ± 5* 256 ± 74†
HGF 51 ± 8 5,752 ± 2,324* 271 ± 40**,†
PlFG 1,218 ± 210 1,123 ± 476† 2,648 ± 477*
Angiogenin 17,13 ± 237 33,102 ± 7,300** 8,722 ± 3,384*,†
Osteoprotegerin 434 ± 5 8,041 ± 5,992 2,049 ± 1,468
Cytokines were quantified in supernatants from tumor necrosis factor alpha
pretreated HUVECs, HUVECS co-cultured with ixmyelocel-T, and ixmyelocel-T
(n ≥3). Values are presented as mean ± standard error of the mean relative to
control. EGF, epidermal growth factor; HGF, hepatocyte growth factor; HUVEC,
human umbilical vein endothelial cell; IXT, ixmyelocel-T; MIF, macrophage migration
inhibitory factor; PDGF, platelet-derived growth factor; PlGF, placental growth factor;
VEGF, vascular endothelial growth factor. *P <0.05, **P <0.01, ***P <0.001 versus
HUVEC. †P <0.05, ‡P <0.01 versus IXT.
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HUVECs, P <0.001 compared with HUVECs + TNFα;
Figure 4A). ROS generation was also examined in HUVECs
stimulated with TNFα by measuring the intensity of
DCFH-DA fluorescence. There was a statistically signifi-
cant increase in ROS concentration in HUVECs treated
with TNFα (34 ± 6% vs. 100 ± 26% of HUVECs, P <0.01
compared with HUVECs + TNFα; Figure 4C). Co-culture
with ixmyelocel-T attenuated the TNFα-induced increase
in ROS concentration in HUVECs (46 ± 4% vs. 100 ± 26%
of HUVECs, P <0.01 compared with HUVECs + TNFα;
Figure 4C). Ixmyelocel-T co-culture also resulted in a
statistically significant increase in the activity of the anti-
oxidant enzyme SOD in TNFα-stimulated HUVECs (1.3
± 0.1% vs. 1 ± 0.1% of HUVECs, P <0.05 compared with
HUVECs + TNFα; Figure 4D). Altogether these data sug-
gest that ixmyelocel-T has the ability to decrease oxidative
stress in endothelial cells.
Nuclear factor (NF)-κB is a transcription factor that
regulates the expression of proinflammatory and anti-
apoptotic genes [17]. NF-κB activation was therefore
determined using an activation ELISA in HUVECs
pretreated with TNFα followed by co-culture with
ixmyelocel-T in order to determine whether ixmyelocel-
T secreted factors act on this pathway. Co-culture with
ixmyelocel-T attenuated the TNFα-induced increase
of pNF-κB (0.83 ± 0.04 vs. 1 ± 0.04 relative to control,
P <0.05 compared with HUVECs + TNFα; Figure 4D),
pIKBα (0.83 ± 0.0 vs. 1 ± 0.2 relative to control, P <0.001compared with HUVECs + TNFα; Figure 4E), and pIKKα
(0.04 ± 0.02 vs. 1 ± 0.23 relative to control, P <0.01 com-
pared with HUVECs + TNFα; Figure 4F) in HUVECs.
Together these data suggest that ixmyelocel-T has the
ability to dampen the inflammatory response in endo-
thelial cells in a paracrine manner.
Ixmyelocel-T promotes blood flow recovery in the hind-
limb model
Although rats in the control group display a compensa-
tory recovery of blood flow recovery, treatment with
ixmyelocel-T promoted remarkable restoration of blood
flow, as the perfusion ratio in the ixmyelocel-T group
was significantly greater than in the control group after
8 weeks (1.01 ± 0.07 vs. 0.67 ± 0.03 perfusion ratio, P <0.05
compared with vehicle; Figure 5A). Consistently, immu-
nohistochemistry revealed that the CD31+ capillary to
muscle fiber ratio was significantly higher in the rats re-
ceiving ixmyelocel-T (1.39 ± 0.2 vs. 0.98 ± 0.1 capillary/
muscle fiber ratio, P <0.05 compared with vehicle;
Figure 5B). Treatment with ixmyelocel-T also resulted
in increased plasma nitrates (32.75 ± 12.44 vs. 6.23 ±
2.84 μM, P <0.05 compared with vehicle; Figure 5C),
indicating that treatment with ixmyelocel-T resulted
in increased NO bioavailability Plasma levels of the
angiogenic growth factor PDGF-BB were significantly
elevated in the ixmyelocel-T-treated group (87 ± 5.9
vs. 37 ± 3.4 pg/ml, P <0.001 compared with vehicle;
Figure 5D). Gene expression of VEGFA was also elevated
in the ischemic limb of the ixmyelocel-T-treated group
(1.5 ± 0.14 vs. 1.0 ± 0.08 relative to control, P <0.01 com-
pared with vehicle; Figure 5E). Together these data suggest
that ixmyelocel-T promotes angiogenesis in ischemic
tissue. Since ixmyelocel-T has been reported previously
to have anti-inflammatory properties, markers of in-
flammation were examined in the ischemic limbs. Gene
expression of the anti-inflammatory marker IL-10 was
increased in the ischemic limb (2.0 ± 0.47 vs. 1.0 ±
0.29 relative to control, P <0.05 compared with ve-
hicle; Figure 5F) and plasma levels of IL-10 trended
upwards (230 ± 55 vs. 149 ± 7.9 pg/ml; Figure 5G) in
the ixmyelocel-T-treated group. Plasma levels of the
oxidative stress marker TBARS were significantly de-
creased in the ixmyelocel-T-treated group (0.03 ± 0.003
vs. 0.04 ± 0.005 μM, P <0.05 compared with vehicle;
Figure 5H).
Survival of transplanted ixmyelocel-T in ischemic limb
muscles
Engraftment and the survival potential of ixmyelocel-T
were examined in the ischemic hind-limb model.
Ixmyelocel-T was labeled with the stable-cell, fluores-
cent tracking dye PKH-26. PKH-positive cells were de-
tected in the ischemic limb 8 days after transplantation
Figure 2 Ixmyelocel-T promotes the angiogenic ability of endothelial cells in vitro. (A) Ixmyelocel-T promotes migration of human umbilical
vein endothelial cells (HUVECs) measured with the in vitro scratch assay (magnification 10×). (B, C, D) Ixmyelocel-T co-culture with HUVECs on
Matrigel induced increased HUVEC branch formation and length (magnification 20×). (E) Ixmyelocel-T promotes the proliferation of HUVECs
(n ≥4). Values presented as mean ± standard error of the mean relative to control. *P <0.05, **P <0.001 versus HUVECs. IXT, ixmyelocel-T.
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to host cells when it is taken up by phagocytosis of
labeled apoptotic cells. To confirm that the PKH-
positive cells were of human origin, immuofluorescent
staining of human nuclear antigen, which specifically
labels human cells, was performed (Figure 6B). Dual-
positive PKH-labeled and HNA-positive cells were
detected in the ischemic limbs. These data suggest that
ixmyelocel-T persists in the ischemic tissue and pro-
motes angiogenesis and regeneration in ischemia.
Discussion
This study demonstrates that bone marrow-derived ex-
panded ixmyelocel-T has angiogenic potential which may
be useful for recovering tissues from ischemia. Ixmyelocel-
T was demonstrated to interact with endothelial cells in a
paracrine manner through secretion of angiogenic growth
factors that promote therapeutic angiogenesis and endothe-
lial repair. This study highlighted the effects ixmyelocel-T
exerts on endothelial cells. Specifically, HUVECs stimulated
by angiogenic factors secreted by ixmyelocel-T exhibited
enhanced migration, proliferation, and tube formation.
Co-culture of HUVECs with ixmyelocel-T also resulted insignificantly increased NO bioavailability, decreased
markers of ROS and inflammation, and reduced apop-
tosis. Most importantly, ixmyelocel-T promoted sig-
nificant blood flow recovery which was maintained for
up to 8 weeks after treatment, and induced capillary
formation in a rat hind-limb ischemia model. All
together these data suggest that ixmyelocel-T could be
useful for the promoting of angiogenesis and tissue
repair in ischemic CV diseases.
Soluble factors play a pivotal role in influencing cells
within the local microenvironment by promoting cell
survival and activating tissue repair [5]. Using an anti-
body array, we identified a panel of proangiogenic
cytokine and growth factors differentially secreted in
co-cultures of HUVECS and ixmyelocel-T. Hepatocyte
growth factor, a growth factor that promotes endothelial
regeneration [18], was significantly upregulated in the
supernatants of HUVECs co-cultured with ixmyelocel-T.
IL-6, which protects endothelial cells from oxidative
stress-induced apoptosis, was significantly increased in
the supernatants of HUVECs co-cultured with ixmyelocel-T
[19]. Ixmyelocel-T secreted elevated levels of IL-8, a cyto-
kine secreted by macrophages that promote angiogenesis






















































































Figure 3 Ixmyelocel-T co-culture results in increased endothelial nitric oxide synthase and nitric oxide production in endothelial cells.
(A) Immunofluorescence of endothelial nitric oxide synthase (eNOS) in co-cultured human umbilical vein endothelial cells (HUVECs) (n ≥3).
(B) eNOS protein (n ≥11). (C) Nitric oxide (NO) generation (n ≥9). (D) Nitrates measured in co-culture supernatants (n ≥8). Values presented as
mean ± standard error of the mean relative to control. *P <0.05, **P <0.01, ***P <0.001 versus HUVECs. Magnification: 20×. IXT, ixmyelocel-T.
Ledford et al. Stem Cell Research & Therapy  (2015) 6:25 Page 9 of 14[20]. Additionally, IL-6 and IL-8 are reported to increase
endothelial progenitor cell homing to areas of ischemia
[21]. The chemokine CXCL5, which promotes angiogen-
esis in ischemic tissues through the recruitment of endo-
thelial cells [22], was found significantly elevated in the
supernatants of HUVECs co-cultured with ixmyelocel-T.
CCL7, a chemokine suggested to improve tissue repair in
ischemia by acting as a homing factor for circulating an-
giogenic cells [23], was also elevated in the supernatant of
HUVECs co-cultured with ixmyelocel-T. Macrophage
migration inhibitory factor, which promotes angiogenesis
through endothelial cell activation and endothelial pro-
genitor cell recruitment [24], was elevated in ixmyelocel-T
supernatants. CL1, which stimulates endothelial pro-
genitor cell tube formation [25], was significantly in-
creased in the supernatants of HUVECs co-cultured
with ixmyelocel-T. Placental growth factor, an angio-
genic factor that stabilizes blood vessels and enhances
vascular endothelial growth factor angiogenic activity
[26], was significantly upregulated in the supernatants
of HUVECs co-cultured with ixmyelocel-T. Angiogenin,
an angiogenic factor that triggers eNOS activity result-
ing in increased NO synthesis [27], was significantly
increased in the supernatants of HUVECs co-cultured
with ixmyelocel-T. Osteoprotegerin, which enhances
the angiogenic effects of ECPs and positively regulates
the formation of new vessels [28], was elevated in
ixmyelocel-T supernatants. PDGF-BB, which increases
endothelial proliferation and migration [29], was signifi-
cantly upregulated in the supernatants of HUVECs co-cultured with ixmyelocel-T. PDGF-BB was also found
to be significantly increased in the blood plasma of
the ixmyelocel-T-treated group. Multiple proangiogenic
cytokines/growth factors released from the multiple cell
populations that make up ixmyelocel-T may synergistic-
ally augment neoangiogenesis.
Therapeutic angiogenesis is essential for tissue recov-
ery after injury, and is dependent on endothelial cells
[30]. Enhancing endothelial proliferation and angiogen-
esis may provide a beneficial approach for the ischemic
complications of atherosclerotic diseases. To validate the
angiogenic activity present in the ixmyelocel-T secre-
tome, various functional assays were utilized. Co-culture
of ixmyelocel-T with HUVECs promoted endothelial cell
migration, tube formation, and proliferation in in vitro
through a paracrine manner. eNOS-derived NO is an
important mediator of ischemic angiogenesis [14].
Co-culture of HUVECs with ixmyelocel-T increased NO
bioavailability by enhancing both eNOS expression mea-
sured by immunostaining and ELISA and activation
measured with the intracellular NO probe and nitrate
formation in the co-culture supernatants. Ixmyelocel-T
treatment also significantly increased plasma nitrates in
the hind-limb ischemia model. The induction of NO
production by ixmyelocel-T has the potential to promote
vascular homeostasis, promoting cell growth and vascular
protection from injury [31]. Altogether, these results
suggest that ixmyelocel-T promotes angiogenesis through
promoting endothelial cell proliferation, migration, tube


























































































































































































Figure 4 Co-culture with ixmyelocel-T decreases apoptosis, oxidative stress, and inflammation in TNFα pretreated endothelial cells.
(A) Apoptosis (n = 6). (B) Viability was decreased with ixmyelocel-T co-culture (n= 6). (C) Ixmyelocel-T co-culture decreased reactive oxygen species
(ROS) generation (n ≥6). (D) Ixmyelocel-T co-culture increased antioxidant superoxide dismutase (SOD) in human umbilical vein endothelial cells
(HUVECs) after tumor necrosis factor alpha (TNFα) stimulation (n ≥4). Protein expression of (E) pNFκB, (F) pIKBa, and (G) pIKKa were all significantly
decreased in HUVECs co-cultured with ixmyelocel-T after TNFα stimulation (n = 3). Values presented as mean ± standard error of the mean relative to
control. *P <0.05, **P <0.01, ***P <0.001 versus HUVECs + TNFα. IXT, ixmyelocel-T.
Ledford et al. Stem Cell Research & Therapy  (2015) 6:25 Page 10 of 14Ischemic CV diseases are the consequence of endothe-
lial damage, and a major case of this damage is oxidative
stress and inflammation [30,32]. Oxidative stress has
been reported to impair endothelial growth and angio-
genesis, and when the ability of the endothelium to
handle ROS is exceeded, the resulting oxidative stress
leads to apoptosis and subsequent cell death [16,33].Rats treated in this study with ixmyelocel-T exhibited
decreased plasma TBARS, a marker of oxidative stress,
and increased expression of the anti-inflammatory cyto-
kine IL-10. Additionally, HUVECs pretreated with TNFα
displayed significant increases in intracellular ROS that
was significantly decreased in HUVECs co-cultured with
































































































































































Figure 5 Ixmyelocel-T promotes blood flow recovery in the rat hind-limb model. (A) Treatment with ixmyelocel-T significantly increased
blood flow recovery measured by laser Doppler (n = 4). (B) Treatment with ixmyelocel-T significantly increased capillary density in the ischemic
limb (10×) (n = 4). (C, D) Treatment with ixmyelocel-T significantly increased plasma nitrates (n = 4) and platelet-derived growth factor (PDGF;
n = 3). (E) Treatment with ixmyelocel-T increased gene expression of vascular endothelial growth factor (VEGF) in the ischemic limb (n = 4).
(F) Gene expression of the anti-inflammatory cytokine interleukin (IL)-10 is significantly increased in the ischemic limb of the ixmyelocel-T-treated
group (n = 4). (G) Circulating levels of IL-10 trended upwards in the ixmyelocel-T-treated group (n = 4). (H) Plasma levels of thiobarbituric acid
reactive substances were significantly decreased in the ixmyelocel-T-treated group (n = 4). Values presented as mean ± standard error of the mean.
*P <0.05 versus vehicle. Magnification: 10×. IXT, ixmyelocel-T; MDA, malondialdehyde.




Figure 6 Analysis of PKH26-labeled ixmyelocel-T in the hind-limb ischemia model. (A) High magnification of labeled ixmyelocel-T (green)
throughout the ischemic limb 8 days after initiation of hind-limb ischemia. Sections were immunostained for type I collagen (purple) and
counterstained with 4′-6-diamidino-2-phenylindole (Blue). (B) Analysis of ixmyelocel-T (red) co-localization with human nuclear antigen (green) in
the ischemic rodent limb. Magnification: 400×. HNA, human nuclear antigen; IXT, ixmyelocel-T.
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formation [34,35]. Intracellular levels of ROS are regu-
lated by the balance between ROS-generating enzymes
and antioxidant enzymes, such as SOD [35]. SOD plays
a pivotal role in preventing cellular damage caused by
ROS through reducing superoxide radicals [34]. When
co-cultured with HUVECs, ixmyelocel-T was able to
increase the activity of SOD, increase cell viability, and
decrease apoptosis. Previous studies have demonstrated
anti-inflammatory activities of ixmyelocel-T [7,8]. NF-
κB, a transcription factor that regulates the expression of
proinflammatory and anti-apoptotic markers, plays a
significant role in driving the inflammatory response
[17,36]. NF-κB is regulated by the association with
inhibitory IκB molecules. It can become activated by
several different signals including TNFα, which leads to
the release of NF-κB from its complex with the IκB
molecules [36]. In this study, TNFα treatment resulted
in a significant increase in NF-κB activation in HUVECs
through the activation of NF-κB, IκBa, and Iκκa. Treat-
ment with ixmyelocel-T significantly reduced NF-κB,
IκBa, and Iκκa activation in TNFα-treated HUVECs.
The inhibitory effect of ixmyelocel-T on the NF-κB
pathway might explain the reduction in ROS formation
and the decrease in apoptosis in HUVECs pretreatedwith TNFα. As a result of these findings, treatment with
ixmyelocel-T may prevent endothelial cell apoptosis in a
paracrine manner, perhaps due to decreased intracellular
ROS, increased antioxidant activity, and decreased NF-κB
activity. These characteristics associated with ixmyelocel-
T may promote therapeutic effects in the treatment of
ischemic CV diseases, where cell survival depends on
the ability of cells to overcome apoptotic triggers, espe-
cially in ischemic tissue.
The aim of the present study was not to access the
benefit of a single factor secreted by the multicellular
cell therapy ixmyelocel-T, but rather to examine whether
the pleiotropic activity of this mixed population of cells
can enhance vessel repair and new vessel growth in is-
chemic tissue. Tissue regeneration is a complex process
involving an interplay between macrophages, stem cells,
and stromal cells, and it is hypothesized that a mixture
of regenerative cells, rather than just a single cell type,
might be more advantageous [7,37]. Ixmyelocel-T con-
sists of a mixture of cells expanded from BMMNCs, spe-
cifically an expanded population of CD90+ stromal cells
and CD14+ macrophages that have been characterized
with a M2-like phenotype [7]. It is thought that the
mixture of cells found in ixmyelocel-T might be more
advantageous in long-term tissue regeneration and
Ledford et al. Stem Cell Research & Therapy  (2015) 6:25 Page 13 of 14repair [7,37]. Specifically, it has been reported that MSCs
secrete factors that regulate angiogenesis, and it has
been demonstrated that MSCs promote angiogenesis
after hind-limb ischemia through secretion of growth
factors [38]. The contribution of myeloid cells in angio-
genesis has also been established previously [39,40].
Monocytes/macrophages promote angiogenesis through
the secretion of angiogenic factors and ECM remodeling
[39]. The novelty and advantage of using ixmyelocel-T
are due to its manufacturing process, which relies on a
small volume of bone marrow aspirate, the unique com-
bination of cell populations including expanded MSCS
and M2-like macrophages, the secretion of a distinct com-
bination of angiogenic and regenerative factors, the ability
to remain anti-inflammatory in the face of inflammatory
challenge, and the substantial angiogenic capacity associ-
ated with the therapy. These beneficial effects position
ixmyelocel-T as an optimal cell therapy for treating severe
ischemic CV diseases where treatment options are limited.
Conclusions
The present study demonstrates that ixmyelocel-T, a
bone marrow-derived expanded autologous multicellular
therapy, promotes blood flow recovery and angiogenesis
in vivo and interacts with human endothelial cells
in vitro in a paracrine manner by enhancing migration,
proliferation, and branch formation. Taken together,
these data support a role for indirect angiogenesis and
endothelial cell protection from ischemic injury as at
least a part of the putative mechanism of action in ische-
mic CV patients.
In conclusion, although the use of therapeutic angio-
genesis with BMMNCs in CLI patients has been estab-
lished, ixmyelocel-T therapy may provide a new aspect
of therapeutic angiogenesis in this patient population
where expanded populations of regenerative cells might
be required.
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